SG
TFFP

StoneX Group’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History

StoneX Group’s Portfolio TFFP Stock Details TFFP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-455
Closed -$12K – 713
2022
Q4 		$12K Buy
+455
New +$21.6K ﹤0.01% 447

Other funds holding TFFP

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

StoneX Group's TFFP Position: Q1 2023 in Review

StoneX Group sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q1 2023, closing a stake of 455 shares — an estimated $12K sold.

StoneX Group first reported a position in TFFP in Q4 2022 and held it in 1 quarter. The position peaked at $12K in Q4 2022. 36 funds tracked by Wall St. Rank hold TFFP as of Q1 2023.

  • StoneX Group reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • StoneX Group sold 455 TFF Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $12K.
  • StoneX Group first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • StoneX Group's TFF Pharmaceuticals, Inc. Common Stock position peaked at $12K in Q4 2022.
  • 36 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.